Press Coverage

From Concept to Clearance: Why It's So Expensive to Develop New CV Drugs

Article about a JAMA study showing new cardiovascular drugs are developed at a cost more than 100-fold higher than the average refers to a paper co-authored by ISMP's senior scientist, Thomas Moore, that examined expenses associated with clinical trials and the factors that contribute to those costs.

For the full text, visit Cardiovascular Business online.

 

More News

Since COVID-19 vaccines were granted emergency use authorization, The Institute for Safe Medication Practices (ISMP) has received reports of errors related to storage, preparation, and administration. Because COVID-19 vaccine errors can result in reduced effectiveness, and other safety implications